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Rat glomerular epithelial cells produce and bear factor H on
their surface that is up-regulated under complement attack
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Rat glomerular epithelial cells produce and bear factor H on
their surface that is up-regulated under complement attack.
Background. Factor H is a potent complement inhibitory
molecule that is primarily produced by the liver and appears
in plasma as a soluble protein. Yet there is evidence that other
cells, including those in the kidney, can produce factor H, and
that it can be cell-associated as well as present as a plasma
protein. Here we studied factor H in rat glomerular epithelial
cells (GEC).
Methods. A polyclonal antibody to factor H was used to
identify factor H protein. A polymerase chain reaction (PCR)-
based strategy was utilized to clone the full-length cDNA of
GEC factor H. The relative quantity of factor H mRNA was
measured by quantitative reverse transcription (RT)-PCR in
cultured GEC exposed to complement activation and in the
passive Heymann nephritis (PHN) model of membranous ne-
phropathy.
Results. By immunofluorescence microscopy, factor H pro-
tein was present on the plasma membranes of cultured GEC.
Based upon Western blot studies, this appeared to be the full-
length 150 kD factor H protein. Factor H cDNA cloned from
GEC was identical to the newly deposited sequence for rat
liver factor H cDNA. In cultured GEC in which complement
was activated, factor H mRNA increased over time. Similarly,
in the PHN model in which complement was activated on GEC
in vivo, factor H mRNA and protein also increased over time.
Conclusion. Cultured GEC and glomeruli express factor H
mRNA and protein. As modeled both in vitro and in vivo in
the rat, factor H is up-regulated in membranous nephropathy.
This is likely to be a direct response of GEC to complement
attack and may represent a protective response of this cell.
Activation of the complement cascade leads to the
production of a number of proteins that contribute to
inflammation. This is beneficial in host defense, but can
be detrimental if activated on self tissue. To prevent this,
a number of naturally occurring complement regulatory
proteins are present to restrict complement activation
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throughout the cascades of the three pathways [1]. A
focal point of regulation is at the level of C3/C5 con-
vertases. This occurs in humans via the actions of the
plasma proteins, factor H and C4-binding protein, and
the cell membrane proteins complement receptor 1 (CR1,
CD35), decay-accelerating factor (DAF, CD55), and
membrane cofactor protein (CD46), all members of the
regulators of complement activation gene family located
on chromosome 1q32 [2]. Each of these family members
have common 60 to 70 amino acid complement control
protein (CCP) modules, containing four invariant cyste-
ines that form two intra-CCP disulfide bonds [2]. These
proteins have natural affinity for C3b and/or C4b which
confers upon them the ability to accelerate the intrinsic
decay of C3/C5 convertases and/or act as a necessary
cofactor for the cleavage and inactivation of C3b and
C4b by factor I.
Human factor H was originally isolated in 1965 as 1H
globulin by Nilsson and Mu¨ller-Eberhard [3], and 10
years later its function was determined by both Whaley
and Ruddy [4, 5] and Weiler et al [6]. Factor H inhibits
the formation and accelerates the decay of C3 con-
vertases, serves as a cofactor for factor I [7], displays
chemotactic activity for monocytes [8], can associate with
extracellular matrix and leukocytes [9], and interacts
with a variety of ligands, such as heparin, C-reactive
protein, and adrenomedullin [10, 11].
Factor H has a number of features relevant to the
glomerulus both in health and in disease. Although
largely produced in the liver, there is detectable factor H
mRNA in the human kidney [12, 13]. Of the cultured
kidney cells, both mesangial cells [13, 14] and proximal
tubular epithelial cells [15] have been documented to
produce factor H mRNA and protein, although the exact
physiologic relevance of these remains to be determined.
Not surprisingly, given that factor H is a major fluid phase
complement regulator, abnormalities in this protein are
associated with several renal diseases. The most consis-
tent associations are with membranoproliferative glomer-
ulonephritis (MPGN) and hemolytic uremic syndrome
(HUS). Both humans with dysfunctional factor H mole-
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cules [10, 16, 17] and animals [18, 19] with factor H
deficiencies develop renal disease with features of MPGN.
These associations of abnormal factor H molecules
with glomerular disease support the commonly held be-
lief that activation of the complement cascade contrib-
utes to immunologically mediated glomerular diseases [20].
Additional circumstantial evidence for this is the pres-
ence of complement activation products in glomeruli and
in urine [21–23]. The use of animal models of glomerular
diseases has strengthened the case for a role of comple-
ment in these conditions. Among the most widely used
model of any glomerular disease is the passive Heymann
nephritis (PHN) rat model of human membranous ne-
phropathy. PHN is induced by injection of heterologous
anti-Fx1A antibodies, which progressively accumulate
on the glomerular epithelial cells (GEC) [24]. Once a
threshold amount of anti-Fx1A has accumulated, com-
plement-dependent damage to the GEC occurs, leading
to impairment of the glomerular permselectivity barrier
to protein passage with consequent development of pro-
teinuria [25–27].
Here we studied rat GEC factor H. Our interest in
this cell is based on its involvement in disease models,
such as membranous nephropathy, and that it resides in
a privileged location with restricted access to plasma
proteins. In this study, we cloned the cDNA for factor H
from rat GEC, and determined its expression in normal
and diseased glomeruli and GEC.
METHODS
Antibodies
Goat anti-human factor H (Quidel Corp., San Diego,
CA, USA), which cross-reacts with rat factor H, was
used in these studies [28]. Because this antibody also
cross-reacts with another member of the factor H family,
which we have termed factor H-related protein (FHRP)
[29], reactivity toward this protein was removed by im-
munoabsorption on a column of recombinant FHRP
bound to Sepharose [29]. Confirmation that the resulting
antibody did not react with FHRP was obtained by West-
ern blotting on recombinant FHRP.
Cell culture
Rat GEC were cultured and characterized as pre-
viously described [30] and for these studies were used
between passages 12 and 30. Cells were cultured in K1
medium, which consists of Dulbecco’s modified Eagle’s
medium (DMEM)/Ham’s F10 (1:1) containing 5% Nu-
Serum and homone supplements [30]. Because of the
presence of bovine factor H in Nu-Serum as shown by
Western blotting using anti-factor H antibodies, factor H
was immunochemically depleted from Nu-Serum for
studies of factor H protein in GEC. To accomplish this,
Nu-Serum was passed over a column of anti-factor H
coupled with Sepharose. Depletion of factor H was veri-
fied by Western blotting of the pass-through, and the
serum was sterile filtered.
Immunofluorescence (IF) staining
GEC cultured in factor H–depleted medium were
fixed at 4C with 2% paraformaldehyde in phosphate-
buffered saline (PBS) for 15 minutes, washed with PBS,
pH 7.2, and incubated with goat anti-factor H IgG or
non-immune goat immunoglobulin G (IgG) as a negative
control for 30 minutes at 22C. After three washes in
PBS, the cells were incubated with fluorescein-conju-
gated rabbit anti-goat IgG antibody (Cappel; ICN Bio-
medicals, Inc., Aurora, OH, USA) and viewed by immu-
nofluorescence (IF) microscopy.
Western blotting
GEC in culture dishes were incubated in PBS con-
taining 1 mmol/L ethylenediaminetetraacetic acid (EDTA)
for 20 minutes at room temperature with periodic agita-
tion, and cells not detached after this time were removed
from the substratum with a rubber policeman. Cells were
washed with PBS, and then solubilized for 15 minutes on
ice in 1 mL PBS, pH 7.2, containing 10 mmol/L EDTA, 10
mmol/L iodoacetamide, 5 mmol/L diisopropylfluorophos-
phate, 1% NP-40. Nuclei and cytoplasmic debris were
pelleted at 14,000  g. Solubilized GEC proteins were
dissolved in nonreducing sample buffer and electropho-
resed through a 7.5% sodium dodecyl sulfate-polyacrim-
ide gel electrophoresis (SDS-PAGE) gel. Normal rat
serum and solubilized normal rat liver proteins were in-
cluded as positive control. To document that the factor H–
depleted culture medium completely lacked factor H, this
was run in a parallel lane. Protein (10 g) was run in
each lane. Proteins were electrophoretically transferred
to a polyvinylidene difluoride membrane (Millipore,
Bedford, MA, USA). After blocking in 5% non-fat milk
in 0.1 mol/L NaCl, 0.02 mol/L Tris, pH 7.2, 0.5% Tween
20 (TBST) overnight, the membrane was incubated for
1.5 hours in polyclonal goat anti-human factor H IgG in
TBST. The membrane was then washed in TBST and
incubated in horseradish peroxidase (HRP)-conjugated
anti-goat IgG (Sigma Aldrich, St. Louis, MO, USA) at
a 1:2000 dilution in TBST for 1.5 hours. Thereafter, the
membrane was washed in TBST and developed using
enhanced chemiluminescence (ECL) reagent (Amersham
Pharmacia Biotech, Piscataway, NJ, USA).
Cloning of a partial length cDNA for rat factor H
Polymerase chain reaction (PCR) primers GSP-F1 and
GSP-R1 (Table 1) were designed from the known se-
quence of mouse factor H (GenBank accession no.
M12660) [31], spanning bases 2556 to 3028, which corre-
sponds to CCP’s 14 to 16 bases of mouse factor H. Total
RNA was isolated from cultured rat GEC using TRIzol
Ren et al: Rat glomerular epithelial cell factor H916
Table 1. Gene-specific primers used in cDNA synthesis and cloning
Primer Sequence
GSP-F 5-GCCCAGGTCCTCAGAAGAGA-3
GSP-F1 5-TGATTGAAACCACCGTGAAA-3
GSP-F2 5-CCTGTGTGAATCCACCACAT-3
GSP-F3 5-GCAAAGATTTATTCCCAATCA-3
GSP-R 5-CCTGGGCGACTTAATAGATCCATG-3
GSP-R1 5-AATAAATGCTGGTCCATCAA-3
GSP-R2 5-TCCAACACAACGAGGCAGAGAGCT-3
GSP-R3 5-TTCCGTGTTCATAACTGCTGGACTCA-3
GSP-R4 5-GGTTCAGGATCCCATCTTCCAT-3
GSP-R5 5-CTGTACAAGTGAACTCCACTGAA-3
reagent (Life Technologies, Inc., Manassas, VA, USA).
cDNA was produced from 5 g of total RNA by reverse
transcription using oligo-dT primers (Life Technologies,
Inc.). Throughout the cloning, cDNA from rat liver and
glomeruli (isolated as described below) were processed
identically as PCR controls. PCR was performed with
20 mmol/L Tris-HCl, 2 mmol/L MgCl2, 100 mol/L of
each deoxynucleotide triphosphate, 0.2M of each primer,
and 2.5 units of Taq polymerase (Sigma Chemical Co.,
St. Louis, MO, USA) for 35 cycles consisting of 1 minute
denaturating at 94C, annealing at 55C for 1 minute, and
extension at 72C for 1 minute. PCR products generated
were electrophoresed through a 1.5% agarose gel and
stained with ethidium bromide.
The PCR product of interest was purified from the
gel using QIAquick gel extraction spin columns (Qiagen,
Santa Clarita, CA, USA), ligated into pCRII-TOPO vec-
tor (Invitrogen, Carlsbad, CA, USA), and used to trans-
form competent Escherichia coli (One Shot TOP 10;
Invitrogen). Positive clones were selected on LB agar
containing 50 g/mL ampicillin and 40 g/mL X-gal.
Plasmid DNA was purified from positive clones and
checked by restriction digestion and PCR. The cloned
DNA was sequenced on an ABI 3100 DNA Sequencer
using the BigDye Terminator Cycle Sequencing kit (Ap-
plied Biosystems, Foster City, CA, USA) and standard
vector primers. Sequence comparisons were made with
Genetics Computer Group software (Madison, WI, USA).
3 and 5 rapid amplification of cDNA ends (RACE)
Because the cDNA clone resulting from the above
strategy was not full length, the rapid amplification of
cDNA ends (RACE) methodology (using kits from Life
Technologies) was performed to obtain overlapping 3
and 5 clones from rat GEC cDNA. The missing 3 se-
quence of the rat factor H cDNA was analyzed using a
3 RACE kit. The first strand of cDNA synthesis was
initiated at the poly(A) tail of rat GEC RNA using an
oligo-dT adapter primer (5-GGCCACGCGTCGAC
TAGTAC(T)17-3). Then, PCR was performed using a
rat factor H specific primer (Table 1) and an abridged
universal amplification primer (5-GGCCACGCGTCG
ACTAGTAC-3) with ELONGASE Enzyme Mix (Life
Technologies, Inc.). For 5 RACE, RNA from rat GEC
was reverse transcribed into cDNA as described above,
except that an antisense rat factor H primer (GSP-R2)
was used in place of an oligo-dT primer. Prior to PCR, a
terminal deoxynucleotidyl transferase (TdT)-tailing step
attached a homopolymeric tail of dCTP to the unknown
5 sequence of rat factor H. The 5 end of rat factor H
was amplified by PCR using an antisense rat factor H
primer (GSP-R3), which annealed 5 to GSP-R2, and 5
amplified anchor primer (5-GGCCACGCGTCGACT
AGTACGGGIIGGGIIGGGIIG-3) with ELONGASE
Enzyme Mix. The 5 RACE product was then generated
by nested PCR using another antisense rat factor H
primer (GSP-R), which annealed 5 to GSP-R3 and the
abridged universal amplification primer. The 3 and 5
RACE products were cloned as described above. Posi-
tive clones were sequenced with standard vector primers
and several of the internal primers listed in Table 1.
Factor H expression in vitro
The expression of factor H mRNA was evaluated in
cultured rat GEC in which complement was activated.
To make these as relevant to PHN as possible, anti-
Fx1A was used as the complement-activating antibody
and conditions were chosen to lead to cell injury but not
death (so-called sublytic injury) [30]. To measure cell
injury, cells were loaded with 8 mol/L biscarboxyethyl
carboxyfluorescein (BCECF) as its membrane permeant
acetoxymethyl ester form (Molecular Probes, Eugene,
OR, USA). Once intracellular, this is de-esterified to
BCECF, which is retained by normal cells. Disruption
of plasma membrane integrity by C5b-9 leads to release
of this 520 dalton marker into the cell medium which
is quantified spectrofluorimetrically [30]. To measure cell
death, the methylthiazole tetrazolium (MTT) colorimet-
ric assay was utilized according to the manufacturer’s
instructions (Sigma Aldrich). Dose response studies indi-
cated that 2.5 mg/mL anti-Fx1A and 2% (vol/vol) normal
human serum were optimal. Even in high concentrations,
rat serum did not lead to appreciable cell injury, which
can be attributed to intrinsic complement regulators that
restrict homologous complement activation [32, 33].
Confluent GEC in 12-well culture dishes were exposed
to 2.5 mg/mL anti-Fx1A in PBS for 30 minutes at 22C.
After washing, cells were exposed to 2% human serum
at 37C. RNA was isolated 1, 2, and 4 hours following
exposure to serum (in triplicates for each time point).
A group of control cells was treated identically, yet ex-
posed to serum that had previously been heated at 56C
for 30 minutes to inactivate complement. For all vari-
ables, parallel sets of cells were treated identically, ex-
cept that they were loaded with BCECF at the same time
as antibody sensitization, supernatants were collected for
BCECF measurements, and cells were used for MTT
uptake.
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Fig. 1. Rat glomerular epithelial cells (GEC)
bear factor H on their surface. Shown are im-
munofluorescence (IF) micrographs of para-
formaldehyde-fixed cultured GEC stained
with (A ) anti-factor H immunoglobulin G
(IgG) or (B ) non-immune goat IgG as a nega-
tive control.
Factor H expression in vivo
The PHN model of membranous nephropathy was
used to evaluate the effects of complement activation
on factor H expression in glomeruli. PHN was induced
by standard techniques in normal rats by injection of
anti-Fx1A at a nephritogenic dose [34]. As a control,
animals were depleted of complement by a series of
injections of cobra venom factor (CVF) [35]. Animals
were given 90 units of CVF (Quidel Corp.) divided into
three equal intraperitoneal doses on the day prior to
antibody administration, and then 30 units daily for the
duration of the study. Adequacy of complement deple-
tion was determined by measuring the total hemolytic
activity of serum after CVF treatment by standard tech-
niques [36] and comparing it to pretreatment values. The
complement-replete animals were given buffer injections
instead of CVF. At 3, 4, 5, and 6 days following injection
of anti-Fx1A, glomeruli were isolated by a technique in
which iron oxide particles were injected into the renal
artery [37], followed by magnetic purification, which re-
sulted in a purity of99% by phase-contrast microscopy.
For every time point, 3 rats were studied.
To examine factor H protein expression, separate
groups of animals were studied either at baseline or 6
days following injection of anti-Fx1A. To rid glomeruli of
blood constituents, including plasma and platelet-associ-
ated factor H, kidneys were thoroughly perfused with
saline prior to glomerular isolation. IF staining was per-
formed for factor H, as well as rat C3, using standard
techniques [34]. Western blotting of solublized glomeru-
lar proteins was performed as described above.
Real-time quantitative (Q) PCR
Quantitative PCR (QPCR) was done on reverse tran-
scribed cDNA from all samples. The primers and probe
for factor H were 5-CAGCCCCCTAAAATTGAACA-3,
5-GGGTCCACAAGGTATTCCAA-3, 5-FAM-TCG
CCCAGGTCCTCAGAAGAGA-TAMRA-3 (Synthe-
gen, Houston, TX, USA). As a commonly used house-
keeping gene, glyceraldehyde phosphate dehydrogenase
(GAPDH) was used to normalize RNA from each sam-
ple, using a primer and probe set from Applied Biosys-
tems. QPCR was performed by standard techniques us-
ing a Cepheid Thermocycler (Cepheid, Sunnyvale, CA,
USA). Standard curves were constructed for cultured rat
GEC and isolated glomeruli. The target messages in un-
known samples were quantified from the standard curves
to determine a relative measure of the starting transcript
quantity. Each sample was then normalized to its own
GAPDH expression, for which a similar standard curve
had been constructed. All samples were calculated rela-
tive to the control sample, which was designated as 1.0.
Statistical methods
Data are shown as mean SEM. The slope of factor H
expression over time was determined for each individual
animal by least squares regression, and the individual
slopes in the two groups were compared with the Mann-
Whitney rank-sum test. A P value 	0.05 was considered
significant.
RESULTS
Rat GEC contain factor H protein
Initial studies examined whether cultured rat GEC
contained factor H protein. Because of the likely rele-
vance of factor H on the surface of cells, and because
our past studies showed that factor H was on the surface
of rodent platelets, we were interested in whether fac-
tor H was on the surface of GEC. As such, cells were
fixed in paraformaldehyde so that the plasma membrane
would not be permeable to antibodies used in the IF
procedure. In addition, because of the presence of fac-
tor H in the culture medium, this was removed prior to
culture to exclude absorption of factor H (bovine in this
case) onto GEC during cell culture. As can be seen in
Figure 1A, cultured rat GEC contained factor H on their
surfaces. This was specific staining, as cells incubated
with normal goat IgG had no staining (Fig. 1B).
Because there are a number of factor H molecules
[38] that the preceding IF studies could not distinguish,
further experiments were performed to evaluate the
size(s) of the proteins identified by anti-factor H antibod-
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Fig. 2. Western blotting to detect factor H. The medium used to culture
glomerular epithelial cells (GEC) (lane 1), normal rat serum (lane 2),
solubilized rat GEC (lane 3), and liver proteins (lane 4) were electropho-
resed (10 g/lane) on a 7.5% sodium dodecyl sulfate-polyacrimide gel
electrophoresis (SDS-PAGE) gel under non-reducing conditions, trans-
ferred to a polyvinylidine difluoride (PVDF) membrane, and probed
using polyclonal goat anti-human factor H antibody. The size of the
protein bands, as judged by molecular weight standards run in parallel,
are indicated.
ies by IF in GEC. As shown in Figure 2, by Western
blotting, polyclonal goat anti-human factor H IgG spe-
cifically reacted with two bands of approximately 115
and 150 kD from solubilized GEC proteins (lane 3).
Positive controls were normal rat serum (lane 2) and rat
liver (lane 4), showing that on a per weight basis, factor H
is more abundant in these two sites than GEC. The
medium used to culture GEC lacked factor H, as shown
in lane 1. The 150 kD band identified from both GEC
and serum undoubtedly represents factor H, while based
upon amino acid sequence data, we believe the smaller
protein is a cleavage fragment of factor H [28].
Cloning of rat factor H cDNA
The PCR strategy was to design primers from regions
in CCP’s 14 and 16 bases of mouse factor H, with the
rationale these areas would be conserved in the rat.
When cDNA prepared from GEC, normal rat glomeruli,
and liver RNA was amplified with the primers, one prod-
uct of 470 base pairs was generated (Fig. 3). With this
single sequence, the subsequent identification of the over-
lapping 3 and 5 clones was achieved using the RACE
strategy outlined in Methods. By 3- and 5-RACE, 1588
and 1343 base pair products were obtained, respectively.
Sequencing of these clones enabled us to determine the
Fig. 3. Polymerase chain reaction (PCR)-based approach to amplify
factor H cDNA. One PCR product with 470 bp was generated from
glomerular epithelial cells (GEC) (lane 1), glomerular cDNA (lane 2),
and liver cDNA (lane 3) using primers derived from mouse factor H.
Size standards were run in lane 4.
Fig. 4. Expression of factor H mRNA in cultured glomerular epithelial
cells (GEC) exposed to complement activation. Cultured rat GEC were
sensitized with anti-Fx1A and then exposed to either 2.5% normal
human serum () or heat-inactivated serum (). After the indicated
times, RNA was harvested for qualitative polymerase chain reaction
(QPCR) determination of factor H and GAPDH mRNA, which pro-
vided the relative transcript abundance of factor H over time. Each
point represents the average of 3 samples with standard error of the
mean (SEM) shown as vertical bars. P 
 0.05 normal serum vs. heat-
inactivated serum.
entire 2924 base sequence of rat GEC factor H, which
turned out to be the same as the recently described
sequence for rat liver factor H (GenBank accession no.
AJ320552) [39, 40]. Thus, rat GEC in culture (as well as
glomerular cells in vivo) have mRNA for factor H. Taken
together with the studies examining factor H protein by
IF, this mRNA appears to be translated into protein
which appears on the GEC surface.
Expression of rat factor H mRNA in rat GEC under
complement attack
In these studies, we examined the fate of factor H
mRNA in GEC in which complement was activated. The
expression of factor H gradually increased over time in
cultured GEC exposed to anti-Fx1A and then comple-
ment (Fig. 4). Under the conditions chosen for these
studies, there was 83.0% release of BCECF with 95.9%
of maximum MTT uptake, consistent with the goals to
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Fig. 5. Expression of glomerular factor H mRNA in passive Heymann
nephritis (PHN). Complement-replete () or -depleted () animals
were injected with anti-Fx1A. After the indicated times, glomerular
RNA was harvested for qualitative polymerase chain reaction (QPCR)
determination of factor H and GAPDH mRNA, which provided the
relative transcript abundance of factor H over time. Each point repre-
sents the average from 3 animals. Where the error bars are not shown,
they fall within the symbol. P 
 0.05 complement-replete vs. -depleted
animals.
induce sublytic injury of GEC while maintaining viability
as judged by the uptake of MTT. This increase in factor H
mRNA was specifically due to complement activation,
as factor H mRNA in cells treated identically, yet ex-
posed to heat-inactivated serum, did not show a signifi-
cant change from baseline with time (Fig. 4).
PHN was used in these studies as a relevant model of
human membranous nephropathy, a disease in which
complement activation occurs in the proximity of GEC,
and to study events induced by complement activation
on GEC in vivo. Just as with cultured GEC exposed
to complement activation by anti-Fx1A, there was an
increase in factor H mRNA at each time point studied
in PHN (Fig. 5). This was most pronounced when the
heterologous disease was at its maximum, which is 6 days
following injection of anti-Fx1A. In addition, animals in
which complement was depleted with CVF had no
change in factor H mRNA over time (Fig. 5). Additional
studies were performed to examine factor H protein in
PHN. In normal rats, there was a moderate amount of
factor H protein in glomeruli (Fig. 6A), which increased
significantly in PHN (Fig. 6B). Although there was some
mesangial staining both at baseline and in PHN, the
increased intensity of factor H staining in PHN extended
to the peripheral capillary wall, similar to where C3 was
found (Fig. 6C), which is known to be activated in the
subepithelial space. Confirmation that factor H protein
was increased in PHN came from Western blotting stud-
ies (Fig. 7), which clearly showed an increase in the 115
and 150 kD factor H protein bands in the 4 rats with
PHN. Taken together, these data show that GEC contain
factor H mRNA, and this is up-regulated and translated
into factor H protein in response to complement activa-
tion in vitro and in vivo.
DISCUSSION
In this study we examined the complement regulatory
protein, factor H, in rat GEC. By RT-PCR and IF stud-
ies, we showed that cultured GEC have factor H mRNA
and protein. Furthermore, by cloning factor H cDNA
and from Western blotting using cross-reactive anti-
human factor H antibodies, it is apparent that GEC have
full-length factor H mRNA, which is capable of being
translated into the mature 150 kD protein. This is impor-
tant as a number of smaller mRNA and protein species
exist, including alternatively spliced products of the fac-
tor H gene and transcripts from separate but related
genes. Related to this is our identification of a 78 kD
protein we termed FHRP, which has a number of similar-
ities to factor H, such as its having complement regula-
tory activity and being produced by GEC [29]. In the
present studies, we were careful that our analyses of
factor H mRNA and protein could not be attributable
to FHRP.
Factor H only contains 20 CCP modules, with no other
domains in its protein structure, such as those that might
confer a transmembrane spanning region or a glycosyl-
phosphatidyl inositol linkage. Despite the lack of diver-
sity in structure, factor H does have a variety of ligands,
including C3b, sialic acid, heparin, and various constit-
uents of microorganisms [9, 41–48]. From our studies, it
is apparent that factor H appears to reside, at least in
part, on the surface of GEC. Given that GEC have fac-
tor H mRNA and, hence, the synthetic capacity to pro-
duce this protein, and our culture conditions were such
that factor H could not appear from the medium, it is
clear GEC produce factor H and display it on their plasma
membranes. This appears comparable to what we have
seen in rodent platelets, although in those studies it was
impossible to exclude absorption of plasma factor H onto
the platelet membrane.
Presumably because it has an extended conformation,
factor H behaves as a 300 kD protein by gel filtration
[4]. As such, factor H is unlikely to have access through
the effective size-selective glomerular capillary wall to
access GEC. The same is true of the other main plasma
complement regulator, the 535 kD C4-binding protein.
Therefore, the ability of GEC to produce complement
regulators locally may be necessary to prevent comple-
ment activation. For instance, although CR1 typically
resides on cells of hematopoeitic and immune lineage,
it is also on GEC [49, 50]. GEC and other glomerular
cells also bear the glyosylphosphatidyl inositol–linked
DAF and CD59 proteins [32, 51, 52]. Clearly, upon com-
plement attack, cultured GEC respond with the produc-
tion of factor H and FHRP [29], which may represent a
defense mechanism.
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Fig. 6. Factor H protein is up-regulated in passive Heymann nephritis (PHN). Shown are immunofluorescence (IF) micrographs in which rat
glomeruli were stained for (A and B ) factor H or (C ) C3 either (A) prior to or (B and C) 6 days after injection of anti-Fx1A.
Fig. 7. Western blotting for factor H in glomeruli of rats with passive
Heymann nephritis (PHN). Solubilized glomeruli (10 g/lane) from
normal rats (N  3) and those with PHN (N  4) were probed with
anti-factor H antibodies. Both 115 and 150 kD factor H bands were
up-regulated in PHN.
Glomerular mesangial cells have also been docu-
mented to produce factor H. In these past studies from
van den Dobbelsteen et al [14] and Timmerman [53],
factor H mRNA was identified and factor H protein
appeared in culture supernatants. Whether these cells
bore factor H on their surfaces was not documented in
these studies. By IF staining in our studies, factor H does
appear to be present in the normal rat mesangium. A
compelling case for factor H being involved in glomeru-
lar diseases such as MPGN and HUS comes from obser-
vations made in patients, as well as more contemporary
genetic and animal studies [10, 16, 18, 19, 54]. It is inter-
esting that the vast majority of polymorphic variants of
factor H that associate with HUS are present in the
terminal (20th) CCP of factor H [54]. This particular
CCP is conserved among the factor H family members,
and has a sialic acid/heparin-binding domain that allows
it to become associated with cells [10, 16]. This consti-
tutes a means by which factor H discriminates non-com-
plement activators from activators. Although still quite
speculative, it is conceivable that these mutations affect
factor H binding to the surfaces of nonactivating cells,
such as those rich in sialic acid, including GEC, and
results in favorable conditions for alternative pathway
activation.
The distinct advantages to studying rodents is that
they can be used to model human diseases, allowing
studies that could never be accomplished in humans. As
a follow-up to our cloning factor H cDNA from cultured
GEC and the finding that GEC respond to complement
activation by increasing factor H mRNA, we examined
the fate of factor H mRNA and protein in an accurate
rat model of membranous nephropathy in which comple-
ment appears to be activated directly on GEC. Just like
with cultured GEC, glomerular cells responded to com-
plement activation by increasing factor H mRNA and
protein. Whether this represents some form of protective
response and/or is an attempt to clear the immune depos-
its is the subject of future studies.
CONCLUSION
Cultured GEC and glomeruli express factor H mRNA.
In the former, it appears that full-length factor H protein
is produced and displayed on the cell surface. As mod-
eled both in vitro and in vivo in the rat, factor H mRNA
is up-regulated in membranous nephropathy, which is
translated into factor H protein. This is likely to be a
direct response of GEC to complement attack. Given
that factor H is a potent complement regulator, this
transcriptional response may represent a mechanism by
which the GEC protect themselves from ongoing com-
plement activation.
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